Catalyst Wire Dossier Catalyst Wire Dossier

INCA33890

· Incyte Corporation
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for INCA33890, covering 2025-12-18 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer [Phase 3]

See pricing